About Nanologica

About Nanologica

Nanologica combines unique know-how in the field of materials technology with a genuine interest in solving real problems in life science. The company works with nanoporous silica which has properties that are attractive in a wide variety of applications. In order to succeed, development work is carried out in close dialog with customers. Nanologica is unique in that it is a world leader in controlling the form, type of porosity and surface area of particles of silica. This competence can be used to produce particles that have the potential to solve problems in diverse application areas. The company’s core competency has been developed and expanded in two areas of application in particular: drug delivery on the one hand and on the other chromatography, a technology used for the separation and purification of products on the market and in development.

The starting point for Nanologica’s work is in material sciences, a field in which the company’s founder has developed and patented completely new materials. The initial research was based at Stockholm University and the Ångström laboratories at Uppsala University.

Vision

Nanologica’s vision is to improve the quality of life for patients undergoing expensive or inadequate treatment for various diseases.

Nanologica combines the expertise in materials sciences together with understanding the end-users’ needs, to improve products and processes in the life sciences industry.

As a world leader in nano-porous particles for drug formulation and chromatography separation, Nanologica aims to make a positive impact to the world by leveraging its expertise for the betterment of mankind

Origin

Nanologica was founded in 2004. The company grew out of Dr. Alfonso Garcia-Bennett’s research, which focused on the synthesis and application of new porous materials and the development of industrially relevant applications.

The starting point for Nanologica’s work is material science, a field in which the company’s founder has developed and patented completely new materials. The initial research was based at Stockholm University and the Ångström laboratories at Uppsala University.

In 2011, Nanologica shifted focus from carrying out research on the material to building a robust commercial operation. A new management team was recruited by 2012, and operations focused on analytical chromatography and drug delivery.

HISTORY:

2004 – 2009

Nanologica underwent an orientation phase during which the various possibilities and options were evaluated. Nanologica started to concentrate its efforts on solar cells and drug delivery. Exeger (solar cells) was formed with Nanologica as the major owner.

2010-2011

The first studies in drug delivery, NLAB Silica™, were carried out. The company’s shareholding in Exeger was distributed to Nanologica’s shareholders.

2012-2015

Since 2012, Nanologica has conducted the NLAB Saga™ development project, which aims to develop a silica particle for chromatographic use, specifically for what is known as analytical chromatography.

Together with a research group at Stockholm University led by Professor Tore Bengtsson, 2012-2014, Nanologica conducted a series of experiments which showed that silica has the potential to treat obesity.

Sigrid Therapeutics, a subsidiary, was founded in 2014 to create a clear and commercial focus for the success in treating overweight and obese individuals.

At the start of 2015, Nanologica received an important confirmation of NLAB Silica™ technology (drug delivery) when a customers decided to take a test project for a generic drug to the clinical development phase.

The project, NanoALS, was launched in 2015. This project has the potential to develop a treatment which would entail ALS no longer being regarded as a fatal disease but a chronic disease.

Management & Team

team member

Andreas Bhagwani

CEO since 2011andreas.bhagwani@nanologica.com

Education and training:
MBA from Stockholm School of Economics, studies in agronomy at the Swedish University of Agricultural Sciences in Uppsala.

Main experience:
Andreas is the co-founder of several companies, the most recent being Sigrid Therapeutics AB (obesity therapy) and Atrogi AB (diabetes). Andreas has worked as a management consultant for over a decade, specialising in sales and leadership. In addition to the above companies, he is a co-founder at Kichisaga Leadership (management consultancy) and GenderTimer (cell phone app).

Other assignments:
Board member and owner of Vega Bianca AB, deputy board member and co-owner of Kichisaga Leadership AB, as well as co-owner of Atrogi AB and Mailendar AB.

Holds 420,841 shares through the company Vega Bianca AB and stock options entitling to 53,422 shares.

team member

Eva Osterman

CFO since 2017eva.osterman@nanologica.com

Education and training:
Master’s degree in Business Administration from Uppsala University.

Main experience:
Eva has many years of experience in finance at larger companies. She has worked within business control, financial control, reporting and internal audit. She also has extensive experience from major international firms in the pharmaceutical industry.

Holds 2,200 shares.

team member

Adam Feiler

CTO since 2012 & Head of Drug Delivery since 2015adam.feiler@nanologica.com

Education and training:
Doctorate in physical chemistry from The Ian Wark Research Institute at the University of South Australia, Adelaide, Australia.

Main experience:
Adam has nearly two decades’ academic research experience in the area of nanoparticles, biomaterials and medical implants. His experience also includes a broad range of analytical methodologies within microscopy and spectroscopy. Adam also has several years’ industrial experience from the Institute for Surface Chemistry (currently SP Chemistry, Materials and Surfaces) as head of research and business manager. Whilst there he was in charge of managing contract research projects within the pharmaceutical, cosmetics and food industries.

Other assignments:
Adam serves as Scientific Advisor to Sigrid Therapeutics and to SwedNanoTech. He is also an adjunct professor at the Royal Institute of Technology (KTH), Stockholm.

Holds 1,000 shares and stock options entitling to 19,372 shares.

Team

The team at Nanologica consists of industry experts with vast knowledge and contributions in the field of Life Sciences.

team member

Janne Blid

Principal Scientist, Chromatographyjanne.blid@nanologica.com
team member

Olga Krivosheeva

Senior Scientist, Chromatographyolga.krivosheeva@nanologica.com
team member

Hanoi Labrador

Senior Project Managerhanoi.labrador@nanologica.com
team member

Nerea Arriaga

Scientist, Drug Deliverynerea.arriaga@nanologica.com
team member

Carita Jagenheim

Projects and Accountingcarita.jagenheim@nanologica.com
team member

Kunal Mukhopadhyay

Head of Global Saleskunal.m@nanologica.com
team member

Sven Petrén

Quality Assurance Managersven.petren@nanologica.com
team member

Paulina Paszkiewicz

Business Area Manager, Drug Deliverypaulina.paszkiewicz@nanologica.com
team member

Xin Xia

Scientist, Drug Deliveryxin.xia@nanologica.com
team member

Chunfang Zhou

Lead Scientist, Drug Delivery & Director of Sales, Chinachunfang.zhou@nanologica.com
team member

Richard Havam

Logistics Managerrichard.havam@nanologica.com

Board of Directors

team member

Gisela Sitbon (1958)

Chairperson of the board
Board member since 2012,
Chairman since 2014

Education and training:
Doctorate in medical sciences from the Karolinska Institute in Solna

Main experience:
Twenty-five years’ experience in the life science industry, of which just over ten years in senior positions (including CEO) at Professional Genetics Laboratory AB and five years as head of section at Karo Bio AB. Business coach in the life science sector at STING AB and responsible for business development for growth companies at her own company ZENZ AB.

Other board appointments:
Chairperson of the board Beactica AB and Lipigon Pharmaceuticals AB, board member of Aifloo AB, CollaboDoc AB and Annexin Pharmaceuticals AB

Holds 12,500 shares through the company Sitbon Bioscience Partner Zenz AB.

team member

Peter von Ehrenheim (1955)

Board member since 2016

Education and training:
Master of Science in Mechanical Engineering from Royal Institute of Technology (KTH), Stockholm.

Main experience:
Head of the separation division at Amersham and GE Healthcare between 2000 and 2006, and CEO of GE Healthcare Life Sciences 2006 to 2011.

Other board appointments:
Chairman of Biolin Scientific AB, Boule Diagnostics AB, VBN Components AB and Robustus Wear Components AB and board member of Biotage AB and Meda AB.

Holds 1,375 shares.

team member

Hans Lennernäs (1960)

Board member since 2014

Education and training:
Doctorate in pharmacy from Uppsala University

Main experience:
Professor of Biopharmacy at the Department of Pharmacy, Uppsala University. Co-founder of, among others, DuoCort Pharma AB and LIDDS AB.

Other board appointments:
Board member of Hans Lennernäs Biomedical AB, Recipharm Pharmaceutical Development AB and Empros Pharma AB

Holds 6,000 shares through the company Hans Lennernäs Biomedical AB.

team member

Lena Torlegård (1963)

Board member since 2014

Education and training:
B.Sc in business
administration from the Stockholm School of Economics

Main experience:
Over 15 years’ experience as a communications consultant, for companies in the life science sector as well. She works primarily with financial communications and corporate communications but also with crisis management and trademark issues. Senior consultant at Springtime AB in Stockholm.

Other board appointments:
Board member of Lytix Biopharma AS

Holds 3,749 shares.

team member

Paula Zeilon (1962)

Board member since 2016

Education and training:
Master of Science in
Chemical Engineering from the Faculty of Engineering (LTH) at Lund University.
Graduate Engineer Program, Stockholm School of Economics.

Main experience:
Thirty years’ experience from the life science industry, of which 14 years within chromatography at Amersham Biosciences, in senior positions within product development and marketing. Paula is one of the founders of the consulting firm Conlega and has since 2000 been working with numerous life science companies with business development and interim management, among others as CEO at Life Science Foresight Institute, CEO at Alligator Bioscience, Director Marketing at Dako A/S, Director Marketing at Biotage and Director Business Development at Amersham.

Other board appointments:
Board member of BioGaia AB.

Holds no shares in Nanologica.

team member

Eva Byröd (1952)

Board Member since 2017

Education and training:
Master of Science in Chemical Engineering Chalmers University of Technology

Main Experience:
More than twenty-five years experience as a line manager in pharmaceutical research and development and ten years experience as a Project Manager/Project Director, working in early as well as late phase pharmaceutical development projects

Holds no shares in Nanologica.

Career

At Nanologica, we are keen to match the right person with the right position and believe in provision of equal opportunities regardless of age, sex, nationality, religion, etc. We are currently a team of 15 talented and committed individuals, evenly distributed between women and men, representing seven different nationalities in total.

Nanologica is growing rapidly and opportunities for people with drive and ambition are being created. As an employee, you will be expected to combine knowledge and skills with creativity and passion to take the company to the next level.

If this sounds interesting, send your application to info@nanologica.com today. We welcome applications from everyone, from apprentices and post-graduate students, to researchers, engineers and industry experts!

Corporate Governance

Select your currency
EUR Euro